Immunocore reports 70% two-year survival with dual T-cell engager combination in uveal melanoma
Immunocore’s brenetafusp plus Kimmtrak posted 70% two-year survival in 17 first-line uveal melanoma patients, prompting a Phase 2/3 trial.
Pharma & Biotech